InMed Pharmaceuticals Inc. (INM) · Nov 19, 2026 · Auditor change
Deloitte engaged — Deloitte appointed for fiscal year ending December 31, 2026
Mentari Therapeutics changed auditors after its InMed reverse merger, appointing Deloitte while reporting no disagreements or reportable events.
Mentari is now a clinical-stage migraine-prevention biotech built around MT-001 and MT-002, following its reverse merger with InMed and a previously announced $490 million financing intended to fund development into multiple 2027 data catalysts.
This is post-merger accounting cleanup, not a change in the operating story. The company dismissed CBIZ, which audited legacy InMed, and Ernst & Young, which audited legacy Mentari, then appointed Deloitte for the December 31, 2026 year-end. The filing says there were no disagreements or “reportable events” involving either outgoing auditor. 〔0〕 〔1〕
The going-concern language is inherited, not a fresh deterioration. Both legacy audit reports contained explanatory paragraphs about substantial doubt over continuing as a going concern, but that disclosure was already attached to the pre-merger entities; this filing does not add a new financial warning or revise the post-merger funding position. The practical test is Deloitte’s first audit of the combined company, whose historical financial statements will be based on Mentari as the accounting acquirer.
Bottom line: The filing formalizes the auditor transition required by the reverse merger but does not materially change the migraine-development story or introduce a new accounting problem. It is routine infrastructure, not a substantive business signal.
First audited December 31, 2026 annual report
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!